Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 2/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL64690 | 0.95 | ABCB1 (0.42) | ABCB1MTORCDC7ALDH1A1ADORA3 | |
| SCHEMBL12293879 | 0.95 | ABCB1 (0.42) | ABCB1MTORCDC7ALDH1A1ADORA3 | |
| SCHEMBL954434 | 0.94 | ABCB1 (0.41) | ABCB1MTORCDC7ALDH1A1ADORA3 | |
| SCHEMBL2680751 | 0.93 | ABCB1 (0.40) | ABCB1CDC7ALDH1A1ADORA3ADORA1 | |
| SCHEMBL13401854 | 0.90 | ABCB1 (0.39) | ABCB1MTORCDC7ALDH1A1ADORA3 | |
| SCHEMBL20841761 | 0.90 | ABCB1 (0.39) | ABCB1CDC7ALDH1A1ADORA3ADORA1 | |
| SCHEMBL20841749 | 0.90 | ABCB1 (0.39) | ABCB1MTORCDC7ALDH1A1ADORA3 | |
| SCHEMBL10196888 | 0.90 | ABCB1 (0.39) | ABCB1CDC7ALDH1A1ADORA3ADORA1 | |
| SCHEMBL10196893 | 0.90 | ABCB1 (0.39) | ABCB1MTORCDC7ALDH1A1ADORA3 | |
| SCHEMBL29887519 | 0.89 | CDC7 (0.43) | ABCB1MTORCDC7ALDH1A1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9645128-B2 | Substituted imidazo[1,2-A]pyrazines for measuring a transcription activity | JNC CORPORATION (JP) | 2017-05-09 | — | — | US | disclosed |
| US-9645128-B2 | Substituted imidazo[1,2-A]pyrazines for measuring a transcription activity | JNC CORPORATION (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20160281129-A1 | LUMINESCENT SUBSTRATE FOR USE IN ARTIFICIAL BIOLUMINESCENT ENZYME | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2016-09-29 | — | — | US | disclosed |
| US-20160281129-A1 | LUMINESCENT SUBSTRATE FOR USE IN ARTIFICIAL BIOLUMINESCENT ENZYME | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2016-09-29 | — | — | US | disclosed |
| US-20150344936-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-12-03 | — | — | US | disclosed |
| US-20150344936-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-12-03 | — | — | US | disclosed |
| US-9151739-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9151739-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20140296521-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | JNC CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296521-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | JNC CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8765921-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765921-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20140024058-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2014-01-23 | — | — | US | disclosed |
| US-20140024058-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2014-01-23 | — | — | US | disclosed |
| US-8546568-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2013-10-01 | — | — | US | disclosed |
| US-8546568-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2013-10-01 | — | — | US | disclosed |
| US-20120035070-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035070-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2012-02-09 | — | — | US | disclosed |
| WO-2010090319-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | チッソ株式会社 (JP) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296521-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | GLB1, CEL, SI | ABCB1 1068/4885MTOR 4256/4885CDC7 2192/4885 |
| US-20160281129-A1 | LUMINESCENT SUBSTRATE FOR USE IN ARTIFICIAL BIOLUMINESCENT ENZYME | GALC, GUSB, GLB1 | ABCB1 3205/4885MTOR 3508/4885CDC7 3588/4885 |
| US-20120035070-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | GLB1, CEL, SI | ABCB1 1068/4885MTOR 4256/4885CDC7 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.